A team from the Department of Neurosurgery at Niigata University has achieved a remarkable result in treating a rare brainstem tumor. The patient came in with a gradual loss of hearing in the left ear. MRI scans revealed a lesion on the left side of the brainstem. Initially, the doctors suspected it was a common type of brainstem glioma with a specific mutation.
However, the symptoms and location of the tumor didn’t match typical cases. A special imaging technique called magnetic resonance spectroscopy showed a marker indicating a rare IDH2 mutation. After conducting a biopsy, the team confirmed this rare mutation. Unlike most brainstem gliomas with a different mutation that resist treatment, tumors with the IDH2 mutation often respond well to temozolomide, a standard cancer drug.
Under the leadership of Dr. Manabu Natsumeda, the patient received treatment with temozolomide and radiation. To everyone’s surprise, not only did the tumor shrink significantly, but the patient’s hearing improved as well. After one year of maintenance treatment, the patient has been off medication, and there’s been no sign of tumor regrowth. “Identifying the IDH mutation was crucial for our treatment decision,” says Dr. Natsumeda. “This case highlights the importance of advanced screening techniques.”
Research shows that around 70% of IDH-mutant astrocytomas have a methylated MGMT promoter, making them more vulnerable to therapies like temozolomide. This case is a reminder of how vital it is to customize cancer treatments based on individual mutations.
This treatment approach may influence future protocols for brainstem gliomas, stressing the significance of genomic screenings. A study in Frontiers in Oncology highlights these findings, paving the way for innovative treatment methods tailored to genetic profiles.
For further reading, you can check out the full study here: Case Report in Frontiers in Oncology.
Source link
Glioma, Hearing, Temozolomide, Tumor, Biopsy, Brain, Mutation, Neurosurgery, Oncology, Promoter, Research
